KOPRAN
|
KOPRAN Last 5 Year Financial Ratios History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | 5.65 | 12.66 | 14.24 | 4.86 | 5.55 |
CEPS(Rs) | 8.29 | 14.96 | 16.60 | 7.07 | 7.58 |
DPS(Rs) | 3.00 | 3.00 | 1.50 | - | - |
Book NAV/Share(Rs) | 91.11 | 88.40 | 56.65 | 43.86 | 38.95 |
Tax Rate(%) | 24.49 | 25.37 | 26.07 | 25.68 | 24.13 |
Margin Ratios | |||||
Core EBITDA Margin(%) | 9.28 | 18.00 | 16.29 | 12.92 | 12.69 |
EBIT Margin(%) | 7.55 | 17.93 | 17.87 | 10.29 | 11.36 |
Pre Tax Margin(%) | 6.46 | 16.88 | 16.63 | 7.82 | 8.85 |
PAT Margin (%) | 4.88 | 12.60 | 12.29 | 5.81 | 6.71 |
Cash Profit Margin (%) | 7.16 | 14.89 | 14.33 | 8.46 | 9.15 |
Performance Ratios | |||||
ROA(%) | 4.32 | 11.62 | 15.22 | 5.84 | 7.27 |
ROE(%) | 6.29 | 18.19 | 28.34 | 11.74 | 15.34 |
ROCE(%) | 8.30 | 21.40 | 30.40 | 13.69 | 16.30 |
Asset Turnover(x) | 0.89 | 0.92 | 1.24 | 1.00 | 1.08 |
Sales/Fixed Asset(x) | 2.53 | 2.66 | 3.30 | 2.54 | 2.76 |
Working Capital/Sales(x) | 2.51 | 1.84 | 4.31 | 4.38 | 4.91 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.39 | 0.38 | 0.30 | 0.39 | 0.36 |
Receivable days | 94.82 | 93.20 | 77.53 | 90.59 | 77.21 |
Inventory Days | 91.76 | 94.14 | 68.65 | 81.75 | 73.66 |
Payable days | 81.67 | 108.83 | 90.60 | 100.26 | 106.92 |
Valuation Parameters | |||||
PER(x) | 19.55 | 22.24 | 7.37 | 5.22 | 7.49 |
PCE(x) | 13.33 | 18.82 | 6.32 | 3.58 | 5.49 |
Price/Book(x) | 1.21 | 3.19 | 1.85 | 0.58 | 1.07 |
Yield(%) | 2.72 | 1.07 | 1.43 | - | - |
EV/Net Sales(x) | 1.08 | 2.88 | 1.04 | 0.54 | 0.76 |
EV/Core EBITDA(x) | 10.85 | 14.03 | 5.15 | 4.08 | 5.52 |
EV/EBIT(x) | 14.12 | 15.82 | 5.73 | 5.19 | 6.71 |
EV/CE(x) | 0.92 | 2.25 | 1.17 | 0.52 | 0.78 |
M Cap / Sales | 0.97 | 2.84 | 0.92 | 0.30 | 0.50 |
Growth Ratio | |||||
Net Sales Growth(%) | 15.38 | -2.91 | 36.81 | 0.45 | 14.23 |
Core EBITDA Growth(%) | -44.02 | -1.77 | 110.80 | -4.18 | 23.50 |
EBIT Growth(%) | -51.50 | -2.99 | 140.82 | -8.51 | 29.14 |
PAT Growth(%) | -55.38 | -0.93 | 193.08 | -12.50 | 17.26 |
EPS Growth(%) | -55.38 | -11.13 | 193.07 | -12.50 | 17.26 |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | 0.17 | 0.17 | 0.27 | 0.47 | 0.58 |
Current Ratio(x) | 2.25 | 2.74 | 1.72 | 1.59 | 1.54 |
Quick Ratio(x) | 1.52 | 1.75 | 1.10 | 0.96 | 1.00 |
Interest Cover(x) | 6.93 | 16.98 | 14.36 | 4.17 | 4.52 |
Total Debt/Mcap(x) | 0.14 | 0.05 | 0.15 | 0.81 | 0.54 |
Compare Financial Ratios of peers of KOPRAN
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
KOPRAN | ₹1,284.5 Cr | -4% | -5.8% | 134% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹364,015.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
CIPLA | ₹108,809.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹99,408.7 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
DIVIS LABORATORIES | ₹98,684.0 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹94,213.7 Cr | 5% | 10.4% | 109.1% | Stock Analytics |
KOPRAN Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
KOPRAN | -4% |
-5.8% |
134% |
SENSEX | -2.9% |
-0.4% |
20% |
You may also like the below Video Courses